Upstream Bio (UPB) Net Income towards Common Stockholders (2023 - 2026)

Upstream Bio's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$61.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 126.57% year-over-year to -$61.8 million; the TTM figure through Mar 2026 stood at -$178.0 million (down 98.49% YoY), while the FY2025 annual figure was -$143.4 million, down 87.76% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$61.8 million, down from -$42.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$6.3 million in Q3 2023, with the low at -$61.8 million in Q1 2026.
• The 4-year median for Net Income towards Common Stockholders is -$21.8 million (2024), against an average of -$27.5 million.
• Peak annual rise in Net Income towards Common Stockholders reached 45.42% in 2024, while the deepest fall reached 236.37% in 2024.
• Upstream Bio's Net Income towards Common Stockholders stood at -$15.0 million in 2023, then plunged by 45.42% to -$21.8 million in 2024, then plunged by 94.86% to -$42.5 million in 2025, then plunged by 45.52% to -$61.8 million in 2026.
• Business Quant data shows UPB's Net Income towards Common Stockholders at -$61.8 million in Q1 2026, -$42.5 million in Q4 2025, and -$33.7 million in Q3 2025.